IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII

Size: px
Start display at page:

Download "IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII"

Transcription

1 IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII Congreso Costarricense de Climaterio Menopausia y osteoporosis 2014 Dr. Leonardo Orozco S. Colaboración Cochrane Iberoamericana

2 OOFORECTOMÍA PROFILÁCTICA Significado Entender que el termino OP implica que los ovarios son normales al tiempo de la escisión quirúrgica. Se realiza por posibles beneficios futuros Datos del Centro de Prevención y Control de Enfermedades en Estados Unidos 1988 a 1993, revelan que la preservación ovárica ocurre solamente en un 40% -50% de las pacientes a quienes se les efectúa histerectomía a los 40 ó más años de edad. Cifras conservadoras sugieren que a mujeres se les hace una ooforectomía bilateral profiláctica cada año.

3 OOFORECTOMÍA PROFILÁCTICA Costa Rica Según la base de datos de egreso hospitalario del Hospital de las Mujeres en San José Costa Rica, se efectúo una ooforectomía bilateral en el 71% de las pacientes de histerectomía entre los años 2003 y 2005 Referencias Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, et al. Hysterectomy surveillance-united States, MMWR 1997; 46: S 4:1-15. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106: AMC, vol 50 (3), julio-septiembre 2008.

4 Rate of bilateral oophorectomy stratified by age in women having hysterectomy for benign disease from 2000 to 2010 Based on retrospective cohort study 752,045 women aged years with hysterectomy for benign disease from 2000 to 2010 evaluated 46.4% had bilateral oophorectomy Rate of bilateral oophorectomy by age < 40 years 25.7% years 37.3% years 59.2% years 74.8% years 74.5% years 69% Rate of bilateral oophorectomy decreased with more recent year of surgery for all age groups CONCLUSION: The rate of ovarian conservation is increasing, particularly among women younger than 50 years old. Reference - Obstet Gynecol 2013 Apr;121(4):717, editorial can be found in Obstet Gynecol 2013 Apr;121(4): 701

5 American College of Obstetricians and Gynecologists (ACOG) recommendations for elective and risk-reducing salpingooophorectomy Factors supporting oophorectomy genetic risk for ovarian cancer based on family history or genetic testing including BRCA mutations or family history of hereditary non polyposis colorectal cancer presence of bilateral ovarian neoplasms severe endometriosis pelvic inflammatory disease or tuboovarian abscesses postmenopausal state? Factors supporting ovarian preservation premenopausal state preservation of fertility impact on sexual function, libido, and quality of life in young women presence of risk factors for osteoporosis in premenopausal women Reference - American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 89 Obstet Gynecol 2008 Jan;111(1):231, reaffirmed 2013 Jan or at National Guideline Clearinghouse 2008 Jun 16:12190)

6 Insufficient evidence to evaluate benefit of hysterectomy plus oophorectomy vs. hysterectomy alone in premenopausal women with benign gynecologic conditions Based on Cochrane review Systematic review of randomized and controlled clinical trials evaluating hysterectomy plus oophorectomy vs. hysterectomy alone in premenopausal women with benign gynecologic conditions Only 1 controlled trial with 362 women included Primary outcomes of mortality or future gynecologic surgical interventions not reported Possible benefit on psychological well-being for both treatment groups at 1 year follow-up, but no differences between groups No randomized trials identified Reference - Cochrane Database Syst Rev 2008 Apr 16;(3):CD005638

7 CARPOMW: Central American Research on Prophylactic Ovariectomy amongst Menopausal Women A clinical trial of bilateral prophylactic ovariectomy versus conservation of the ovaries amongst menopausal participants that will undergo an elective hysterectomy Authors: Background What is a Prophylactic Ovariectomy? A prophylactic ovariectomy implies that the ovaries are normal at the time of the surgery and that it is performed for a future protective benefit. Current medical practice supports 45 years as the age at which a prophylactic ovariectomy should be strongly recommended. Current Practices The predominant teaching is that prophylactic ovariectomy in participants with low risk of ovarian cancer must be avoided in women under 40 years old, routinely performed in women over 50 years old, and is individualized in between. However, despite the fact that this is a widespread practice, current scientific evidence supporting prophylactic ovariectomy is weak, and is the result of research amongst pre-menopausal women. The debate regarding short- and long-term effects of prophylactic ovariectomy remains unresolved. The decision to perform this intervention is based more on opinion than on methodologically high quality studies. Rationale This prospective, randomized, and multi-centre controlled study attempts to evaluate the short- and long-term effects that prophylactic ovariectomy has on the quality of life and sexual well-being of the post-menopausal woman. Objectives To establish the extent to which prophylactic ovarietomy affects patient-reported outcomes associated with overall well-being and healthrelated quality of life amongst post-menopausal women. Design A prospective, randomized, multicentre controlled study. This study will be carried out in hospitals in Costa Rica, El Salvador, Panama, and Uruguay. Research Flowchart Participants that undergo a hysterectomy are eligible if: 1. They are between 45 and 65 years old. 2. They will undergo an elective hysterectomy for a benign cause. 3. Woman has provided written informed consent to participate in the study Hysterectom y and Prophylactic Ovariectomy Monitoring (2 yrs) Complete Monitoring (5 yrs) Informed Consent Randomization 1st Publication 2nd Publication Hysterectomy (without Prophylactic Ovariectomy) Monitoring (2 yrs) Complete Monitoring (5 yrs) Study Characteristics Inclusion Criteria 1 Women about to have an elective hysterectomy for benign causes shall be considered. 2. Woman has provided written informed consent to participate in the study. 3. Woman has or is not had a menstrual period for 12 months or more Exclusion Criteria 1. The woman is currently participating or has participated in an investigational trial during the previous four months 2. The woman in the judgment of the principal investigator, is unlikely to be able to be prospectively followed for a five year period 3. The woman has a previous family history of first grade ovarian cancer 4. The woman has antecedents of psychiatric disease and the use of psychotropic drugs. 5. The woman requires a hysterectomy due to the presence of neoplasia. Endpoints physical health, psychological health, family environment, sexual relationships, social support requirement, requirement for further pelvic surgical intervention. Acknowledgements We are grateful for the help of the Cochrane Menstrual Disorders and Subfertility Group, especially for the support of Jane Clark, Review Group Coordinator.

8

9 Bilateral oophorectomy associated with decreased risk of breast and ovarian cancer but increased risk of all-cause mortality Based on prospective cohort of 29,380 female participants in Nurses' Health Study who underwent hysterectomy for benign disease 24 year follow-up Bilateral oophorectomy associated with increased total mortality fatal and nonfatal coronary heart disease lung cancer total cancer mortality For those never having used estrogen therapy, bilateral oophorectomy before age 50 years was associated with an increased risk of all-cause mortality, CHD, and stroke Bilateral oophorectomy associated with decreased breast cancer ovarian cancer all cancers Reference - Obstet Gynecol 2009 May;113(5):1027

10 BILATERAL OPHORECTOMY VS OVARIAN CONSERVATION 1.12 (95% [CI] ) for total mortality 1.17 (95% CI ) for fatal plus non fatal CHD Lung cancer incidence (HR=1.26, 95% CI , number needed to harm=190) Total cancer mortality (HR=1.17, 95% CI ) Reference - Obstet Gynecol 2009 May;113(5):1027

11 BILATERAL OPHORECTOMY VS OVARIAN CONSERVATION Breast cancer (HR 0.75, 95% CI ) Ovarian cancer (HR 0.04, 95% CI , number needed to treat=220) Total cancers (HR 0.90, 95% CI ) Risk of dying of other cancers exceeded the risk of dying from ovarian cancer (low incidence) and breast cancer (high longterm survival rate).

12 Bilateral oophorectomy may increase risk of all-cause mortality, particularly in never-users of estrogen therapy with hysterectomy for benign disease before age 50 years Based on cohort study of 30,117 female participants in Nurses' Health Study who underwent hysterectomy for benign disease 28-year follow-up Bilateral oophorectomy associated with increased risk of all-cause mortality (hazard ratio [HR] 1.13, 95% CI ) All-cause mortality in women < 50 years old at time of hysterectomy who never used estrogen therapy (HR 1.41, 95% CI ) assuming a 35-year lifespan after oophorectomy: number needed to harm for all-cause death=8, coronary heart disease death=33, and lung cancer death=50 Reference - Obstet Gynecol 2013 Apr;121(4):709, editorial can be found in Obstet Gynecol 2013 Apr;121(4):701

13 Insufficient evidence to suggest bilateral oophorectomy is associated with risk of coronary heart disease Based on systematic review limited by heterogeneity Systematic review of 7 observational studies (including 3 large prospective cohorts) evaluating association between bilateral oophorectomy and risk of coronary heart disease 4 studies found increased risk in sub-groups 3 limited studies found no increased risk heterogeneity of trials did not allow meta-analysis Reference - Am J Obstet Gynecol 2009 Feb;200(2):140e1

14 Based on cohort of 25,448 postmenopausal women without family history of ovarian cancer from Women's Health Initiative Observational Study 56% had hysterectomy with oophorectomy 44% had hysterectomy with ovary conservation 78% were current or past users of estrogen and/or progestin mean follow-up 7.6 years incidence of ovarian cancer 0.02% in women with oophorectomy vs. 0.33% in women without oophorectomy (p < 0.05, NNT 323) no significant differences in total cancer, breast cancer, colorectal cancer or lung cancer, all-cause mortality, cardiovascular disease, cardiovascular surgery, stroke, hip fracture. oophorectomy associated with trend toward reduced risk of breast cancer in subgroup of women who had hysterectomy at < 40 years old (hazard ratio 0.72, 95% CI ) CONCLUSIONS: In this large prospective cohort study, BSO decreased the risk of ovarian cancer compared with hysterectomy and ovarian conservation, but incident ovarian cancer was rare in both groups. Our findings suggest that BSO may not have an adverse effect on cardiovascular health, hip fracture, cancer, or total mortality compared with hysterectomy and ovarian conservation. Reference - Arch Intern Med 2011 Apr 25;171(8):760

15 Long-term incidence of oophorectomy appears similar in women with hysterectomy for benign indications compared to women without hysterectomy Based on cohort study 4,931 women with ovary-sparing hysterectomy for benign indications from 1965 to 2002 compared with 4,931 similar women without hysterectomy median follow-up 19.6 years for women with hysterectomy and 19.4 years for women without hysterectomy comparing women with vs. without hysterectomy, cumulative incidence of oophorectomy: 3.5% vs. 1.9% at 10 years after hysterectomy (not significant) 6.2% vs. 4.8% at 20 years after hysterectomy (not significant) 9.2% vs. 7.3% at 30 years after hysterectomy (not significant) Reference - Obstet Gynecol 2013 May;121(5):1069

16 Gracias

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

Managing the adnexae at the time of hysterectomy for benign gynaecological disease

Managing the adnexae at the time of hysterectomy for benign gynaecological disease Managing the adnexae at the time of hysterectomy for benign gynaecological disease This statement has been developed and reviewed by the Women s Health Committee and approved by the RANZCOG Board and Council.

More information

Ask the Experts Obstetrics & Gynecology

Ask the Experts Obstetrics & Gynecology 1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,

More information

North American Menopause Society (NAMS)

North American Menopause Society (NAMS) North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College

More information

Oophorectomy or salpingectomy which makes more sense?

Oophorectomy or salpingectomy which makes more sense? Oophorectomy or salpingectomy which makes more sense? During hysterectomy for benign indications, many surgeons routinely remove the ovaries to prevent cancer. Here s what we know about this practice.

More information

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing

More information

Long-Term Health Outcomes of Surgical Menopause

Long-Term Health Outcomes of Surgical Menopause Long-Term Health Outcomes of Surgical Menopause Vanessa Jacoby, MD, MAS Associate Professor Obstetrics, Gynecology, and Reproductive Sciences University of California, San Francisco None Disclosures Overview

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

What is the gynecologist s role in the care of BRCA previvors?

What is the gynecologist s role in the care of BRCA previvors? What is the gynecologist s role in the care of BRCA previvors? Here, your patient s options for surgery and your best options for her follow-up care and ongoing surveillance OBG Manag. Sept 2013;25(9):10-14.

More information

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were

More information

Tumori eredofamiliari: sorveglianza di donne ad alto rischio

Tumori eredofamiliari: sorveglianza di donne ad alto rischio Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Is It Time To Implement Ovarian Cancer Screening?

Is It Time To Implement Ovarian Cancer Screening? Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya

More information

WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro

WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published

More information

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopause and HRT. John Smiddy and Alistair Ledsam Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation

More information

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention 6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology

More information

Risk-reducing surgery and hormones

Risk-reducing surgery and hormones Risk-reducing surgery and hormones Nora Johansen Registrar and PhD student at Department of Obstetrics and Gynecology, Sørlandet Hospital Arendal, Norway No conflicts of interest to declare Overview Hereditary

More information

Surgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy

Surgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards

More information

Inherited Ovarian Cancer Diagnosis and Prevention

Inherited Ovarian Cancer Diagnosis and Prevention Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics

More information

Policy #: 259 Latest Review Date: November 2009

Policy #: 259 Latest Review Date: November 2009 Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer

More information

Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer

Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer G. Kevin Donovan, MD, MA Kevin FitzGerald, SJ, Ph.D., Ph.D. Daniel Sulmasy, MD, Ph.D. Ovarian cancer has the highest mortality rate of all

More information

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women

More information

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic

More information

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Policy Number: 4.01.17 Last Review: 11/2013 Origination: 11/2007 Next Review: 11/2014 Policy Blue Cross and Blue Shield

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Hormone replacement therapy and breast density after surgical menopause

Hormone replacement therapy and breast density after surgical menopause Hormone replacement therapy and breast density after surgical menopause Freya Schnabel*; Sarah Pivo; Esther Dubrovsky; Jennifer Chun; Shira Schwartz; Amber Guth; Deborah Axelrod Department of Surgery,

More information

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea. Original Policy Date

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea. Original Policy Date MP 4.01.10 Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

More information

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives

More information

Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program

Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program A B C D USPSTF recommends the service. There is high certainty that Offer or provide

More information

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,

More information

OVARIAN CANCER Updates in Screening, Early Detection and Prevention

OVARIAN CANCER Updates in Screening, Early Detection and Prevention UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for

More information

HORMONE REPLACEMENT THERAPY

HORMONE REPLACEMENT THERAPY TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

More information

Borderline Ovarian Tumours. Andreas Obermair Brisbane

Borderline Ovarian Tumours. Andreas Obermair Brisbane Borderline Ovarian Tumours Andreas Obermair Brisbane Definition First described in 1929 Cellular features of malignancy Cellular atypia Mitotic activity No stromal invasion An entity per se??? (or precursor

More information

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea

Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Page: 1 of 7 Last Review Status/Date: June 2015 for Primary and Secondary Dysmenorrhea Description Two laparoscopic surgical approaches are proposed as adjuncts to conservative surgical therapy for the

More information

Complete Summary GUIDELINE TITLE. Cervical cytology screening. BIBLIOGRAPHIC SOURCE(S)

Complete Summary GUIDELINE TITLE. Cervical cytology screening. BIBLIOGRAPHIC SOURCE(S) Complete Summary GUIDELINE TITLE Cervical cytology screening. BIBLIOGRAPHIC SOURCE(S) American College of Obstetricians and Gynecologists (ACOG). Cervical cytology screening. Washington (DC): American

More information

What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy

What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy Familial Cancer (2011) 10:79 85 DOI 10.1007/s10689-010-9384-z What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy Danielle Campfield Bonadies Anne Moyer

More information

Management of Endometrial Hyperplasia

Management of Endometrial Hyperplasia Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New

More information

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility

More information

Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be

Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be Recent studies have led to the development of a new paradigm for the pathogenesis and origin of EOC, based on a dualistic model of carcinogenesis that divides EOC into 2 broad categories designated types

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology

More information

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2010 Factors Associated with Early Versus Late

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial DOI: 10.1111/1471-0528.12598 www.bjog.org Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial

More information

Adult Female Preventive Health Guidelines

Adult Female Preventive Health Guidelines 2016-2017 Adult Female Preventive Health Guidelines Important Note Health Net s Preventive Health Guidelines provide Health Net members and practitioners with recommendations for preventive care services

More information

ARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority:

ARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1 ARIC STUDY MANUSCRIPT PROPOSAL # 714 PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1. a. Full Title: Effect of menopausal status on mood: The influence of demographic

More information

A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy

A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy American Journal of Obstetrics and Gynecology (2006) 194, 711 7 www.ajog.org A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy Cynthia M. Farquhar, MBChB, FRANZCOG,

More information

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014 Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed

More information

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen

More information

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence 2.1 BMI and Breast Cancer Risk BMI is routinely used to qualify an individual s adiposity, yet it is simply a measure

More information

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1 American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations

More information

Clinical Policy Title: Prophylactic salpingo-oopherectomy

Clinical Policy Title: Prophylactic salpingo-oopherectomy Clinical Policy Title: Prophylactic salpingo-oopherectomy Clinical Policy Number: 13.03.03 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: November 16, 2017

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. How Should We Approach Cervical Cancer Screening and Routine Pelvic Examinations in 2019? Michael Policar, MD, MPH Professor Emeritus Department of Obstetrics, Gynecology and Reproductive Sciences University

More information

Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer

Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast

More information

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St

More information

Chemo-endocrine prevention of breast cancer

Chemo-endocrine prevention of breast cancer Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;

More information

--- or not, and do we need to come up with newer strategies for ovarian cancer screening.

--- or not, and do we need to come up with newer strategies for ovarian cancer screening. My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to

More information

HYSTERECTOMY FOR BENIGN CONDITIONS

HYSTERECTOMY FOR BENIGN CONDITIONS UnitedHealthcare Commercial Medical Policy HYSTERECTOMY FOR BENIGN CONDITIONS Policy Number: 2018T0572G Effective Date: September 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

Hereditary Gynecologic Cancer 15 Years of Progress

Hereditary Gynecologic Cancer 15 Years of Progress Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,

More information

Histopathological Study of Hysterectomy Operations in A University Clinic in Tehran From 2005 to 2009

Histopathological Study of Hysterectomy Operations in A University Clinic in Tehran From 2005 to 2009 Histopathological Study of Hysterectomy Operations in A University Clinic in Tehran From 2005 to 2009 Mahmoud Khaniki; M.D. 1, Mahsa Shojaie; M.D. 2, Azam M Tarafdari; M.D. 3 1 Department of Pathology,

More information

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate The Oncologist Review and Commentary Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate M. STEVEN PIVER Department of Gynecologic Oncology, Gilda

More information

patient education Fact Sheet

patient education Fact Sheet patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are

More information

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY

More information

Physiology of Menopause

Physiology of Menopause 6/4/18 21 Physiology of Menopause Timothy Rowe University of British Columbia 6/4/18 22 I have received consulting fees and honoraria for speaking from Pfizer Canada Inc. I have no other competing or potentially

More information

Clinical Policy Title: Prophylactic salpingo-oopherectomy

Clinical Policy Title: Prophylactic salpingo-oopherectomy Clinical Policy Title: Prophylactic salpingo-oopherectomy Clinical Policy Number: 13.03.03 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016

More information

30 TPHA Journal Volume 65, Issue 2

30 TPHA Journal Volume 65, Issue 2 Utilization of BRCA testing in older women with breast and/or ovarian cancer in the state of Texas Ana M. Rodriguez,¹ Sharon H. Giordano,² and Catherine D. Cooksley³ ¹Department of Obstetrics & Gynecology,

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

NATIONAL GUIDELINE CLEARINGHOUSE (NGC) GUIDELINE SYNTHESIS SCREENING FOR BREAST CANCER

NATIONAL GUIDELINE CLEARINGHOUSE (NGC) GUIDELINE SYNTHESIS SCREENING FOR BREAST CANCER NATIONAL GUIDELINE CLEARINGHOUSE (NGC) GUIDELINE SYNTHESIS SCREENING FOR BREAST CANCER Guidelines 1. American Cancer Society (ACS). (1) ACS guidelines for breast cancer screening: update 2003. (2) American

More information

HYSTERECTOMY FOR BENIGN CONDITIONS

HYSTERECTOMY FOR BENIGN CONDITIONS HYSTERECTOMY FOR BENIGN CONDITIONS UnitedHealthcare Oxford Clinical Policy Policy Number: SURGERY 104.7 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...

More information

Removing Unnecessary Barriers to Contraceptive Services

Removing Unnecessary Barriers to Contraceptive Services Title X Grantee Meeting July 31, 2013 Seattle, WA Removing Unnecessary Barriers to Contraceptive Services Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine policarm@obgyn.ucsf.edu

More information

Treatment issues for women with BRCA germline mutation

Treatment issues for women with BRCA germline mutation Treatment issues for women with BRCA germline mutation Overview Fertility and reproductive lifespan The impact of reproductive life on breast and ovarian cancer risk Screening recommendations during pregnancy

More information

Something has changed? The literature from 2008 to present?

Something has changed? The literature from 2008 to present? Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

Does Hysterectomy Lead to Weight Gain or Does Overweight Lead to Hysterectomy?

Does Hysterectomy Lead to Weight Gain or Does Overweight Lead to Hysterectomy? Dr Janneke BERECKI D Fitzgerald, J Berecki, R Hockey and A Dobson 1 1 School of Population Health, Faculty of Health Sciences, University of Queensland, Herston, QLD, Australia Does Hysterectomy Lead to

More information

BRCA mutation carrier patient: How to manage?

BRCA mutation carrier patient: How to manage? BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE

More information

Influence of hysterectomy on long-term fracture risk

Influence of hysterectomy on long-term fracture risk Influence of hysterectomy on long-term fracture risk L. Joseph Melton III, M.D., a Sara J. Achenbach, M.S., b John B. Gebhart, M.D., c Ebenezer O. Babalola, M.D., c Elizabeth J. Atkinson, M.S., b and Adil

More information

Effect of Oophorectomy on Survival After Breast Cancer

Effect of Oophorectomy on Survival After Breast Cancer Research Original Investigation Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, PhD; Henry T. Lynch, MD; William D. Foulkes, MBBS, PhD; Nadine

More information

Women s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD

Women s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD Women s Health: Breast Cancer Screening K. Rast, MD and E. McNany, MD 2013 2017 Update: Who? How? When? Cases and Practice Questions Question 1 A 40 year old female comes to your office for a well woman

More information

Lynch Syndrome. Angie Strang, PGY2

Lynch Syndrome. Angie Strang, PGY2 Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system

More information

WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF

WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS Judith Walsh, MD, MPH Professor of Medicine UCSF OVERVIEW Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature

More information

The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010

The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010 The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010 Table of Contents Topic Page Introduction 2 Abbreviations 2 USPSTF Grades of Recommendations

More information

Research. Breast cancer represents a major

Research. Breast cancer represents a major Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.

More information

Riesgo de CA mamario y Terapia Hormonal actual

Riesgo de CA mamario y Terapia Hormonal actual Riesgo de CA mamario y Terapia Hormonal actual por Manuel Neves-e-Castro VI Congreso Colombiano de Menopausia Colombia, Marzo 3, 2005 BREAST CANCER Risk factor Relative risk Increase incidence Body weight-normal

More information

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Current Concept in Ovarian Carcinoma: Pathology Perspectives Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian

More information

Transfusion triggers in acute coronary syndromes: The MINT trial

Transfusion triggers in acute coronary syndromes: The MINT trial Transfusion triggers in acute coronary syndromes: The MINT trial Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal Objectives Review evidence on transfusion triggers

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

Screening and prevention of ovarian cancer

Screening and prevention of ovarian cancer Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in

More information

Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer Executive Summary

Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer Executive Summary Evidence Report/Technology Assessment Number 212 Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer Executive Summary Background Ovarian cancer is the eighth most common cancer in women

More information

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence: Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion

More information

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer? Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL

More information

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer

More information

Ms. Y. Outline. Updates of SERMs and Estrogen

Ms. Y. Outline. Updates of SERMs and Estrogen Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension

More information